All News
Emerging Therapies in Spondyloarthritis: A Promising Pipeline
Growing awareness of spondyloarthropathies over the last two decades has led to a better understanding of the pathophysiology of spondyloarthritis, and subsequently increased interest in more distinct, disease state specific treatment options.
Read Article
RheumNow Podcast - ACR 2021 Rehash (the good stuff..)
The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.
Read Article
Monitoring Infliximab Drug Levels Improves Efficacy
Should we start considering therapeutic drug monitoring when prescribing TNFi for treatment of our rheumatologic conditions?
Read Article
Uveitis and Prevalence of Psoriasis in axSpA: Dr. Robert Chao ( @doctorRBC) discusses the best SpA abstracts he saw at the #ACR21 annual meeting: abstracts #1324 and #1311.
https://t.co/6zARkjsoCg
Links:
Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis Panel Discussion- #ACR21 Meeting
https://t.co/tNckQa4mCK https://t.co/xgiKDXjtvA
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Updates on New Treatments for SpA: Drs. Antoni Chan ( @synovialjoints) interviews Dr. Laura Coates discuss a number of studies related to new treatments for SpA presented at the #ACR21 annual meeting.
https://t.co/aCK1RRvTaW https://t.co/X1TlY88Jng
Links:
Dr. John Cush RheumNow ( View Tweet)
Best of SpA Abstracts Day 2: Dr. Robert Chao ( @doctorRBC) shares the best of SpA Abstracts from Day 2 of #ACR21.
https://t.co/8oZipxMLCm https://t.co/jAifqBRgVc
Links:
Dr. John Cush RheumNow ( View Tweet)
Updates on New Treatments for SpA: Drs. Antoni Chan ( @synovialjoints) interviews Dr. Laura Coates discuss a number of studies related to new treatments for SpA presented at the #ACR21 annual meeting.
https://t.co/mOutSekQkJ https://t.co/JG18q9PsdD
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI: New Insights into Uveitis in Spondyloarthritis
There have been some updates on uveitis in SpA at #ACR21 shared by Dr. Antoni Chan ( @synovialjoints).
https://t.co/lyKt8p5s4o https://t.co/A9tRmD4mBJ https://t.co/TZPThjrazR
Links:
Dr. John Cush RheumNow ( View Tweet)
ICYMI:Identifying Gaps in axSpA: Lessons from European Map of Axial Spondyloarthritis (EMAS)
Dr. Sheila Reyes(@RHEUMarampa) discusses the three interesting abstracts were presented by the group of Prof. Marco Garrido-Cumbrera on the EMAS at #ACR21.
https://t.co/5kOv5BUU4P https://t.co/lKuXC0mLRt
Links:
Dr. John Cush RheumNow ( View Tweet)
Radiographic Progression in SpA: Dr. Antoni Chan ( @synovialjoints ) discusses abstract #0907 and #0897 presented at the #ACR21 annual meeting.
https://t.co/9hStWrfPOW https://t.co/XkgDjXE7Aq
Links:
Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis Roundtable Rehash of #ACR21
New therapies, delay in diagnosis, artificial intelligence in reading radiographs and MRIs, and more. Panelists includes Dr. Alexis Ogdie-Beatty, Dr. Jose Scher, Dr. Jack Cush and Dr. Christopher Ritchlin.
https://t.co/K0pbddzLAF https://t.co/fS6wBNWOdJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Predictors to Flare in SpA: Dr. Antoni Chan ( @synovialjoints ) discusses abstracts #0929 and #0916 presented at the #ACR21 annual meeting.
https://t.co/C0NLSTzlW9 https://t.co/3BiW2L6BJu
Links:
Dr. John Cush RheumNow ( View Tweet)
Drug retention of TNFi vs. secukinumab in AxSpA pts
Abs#911
⭐️46% discontinued either treatment
⭐️TNFi with slightly better drug retention
⭐️Age, BASDAI, BMI did not favor any group
⭐️inefficacy - main reason
#ACR21 @RheumNow https://t.co/ynoomYrTvX
Robert B Chao, MD doctorRBC ( View Tweet)
Dr. Alexis Ogdie on opioid use in PsA and axSpA, highlighting need for better interventions.
🔹21% of PsA pts (n=828) and 27% of axSpA (n=334) reported prescription opiate use.
🔹⬆️BASDI & HAQ-DI =>⬆️opiate use & costs
https://t.co/Id658ocDVf
#ACR21 Abst1777 @RheumNow
Pedro Castillo _Castillo_Pedro ( View Tweet)
AxSpA/ PsA pts who completed ePRO Q between 2018-2021 showed 🔽 trend of PRO mostly in pts on biologic Rx
If ASDAS < 1.3 /PSAID-12 < 2➡️ pts were seen less frequently
⭐️🔽 clinic workload and better disease activity stratification
Abst # 1788 #ACR21 @RheumNow #ACRBest https://t.co/ilSrOjHQAk
swethaann23 swethaann23 ( View Tweet)
Dose Tapering of TNFi in AxSpA: Dr. Antoni Chan ( @synovialjoints) discusses abstract #0364 presented at the #ACR21 annual meeting.
https://t.co/pDnKFfeQdP https://t.co/7CZg2lkSFI
Links:
Dr. John Cush RheumNow ( View Tweet)
Hospitalisation for heart failure ⬆️ in inflammatory diseases. RA>PsA>AS>PsO . HRs 1.1-1.6 compared to general population. Abstr#1925 #ACR21 @RheumNow https://t.co/kKlGQM5Tcg
Richard Conway RichardPAConway ( View Tweet)
Why is there more CHF in #RheumatoidArthritis ? Also dose response between highest inflammation RA the PsA then axSpA then PsO. ?Cytokine profile varying with disease and maybe CRP. Who knows. Abst#1925 #ACR21 @RheumNow https://t.co/JIH3qwkLpx
Janet Pope Janetbirdope ( View Tweet)
Should we be measuring drug levels in pts taking infliximab?
⭐️Drug monitoring vs. standard dosing showed 73% sustained control vs. 55% (RA, PsA, SpA, UC, Crohn's, PsO)
#ACR21
Abs#1946
#ACRBest @RheumNow
https://t.co/sWMen50ljP https://t.co/F4Wpqis3id
Links:
Robert B Chao, MD doctorRBC ( View Tweet)
